Caring Ambassadors Hepatitis C Program Newsletter
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C type 1 and 4 patients with slow virological response. Ferenci P, Laferl H, Scherzer TM, et al. Gastroenterology. 2009 Nov 9. [Epub ahead of print]
Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Mederacke I, Wursthorn K, Kirschner J, et al. Liver Int. 2009 Nov;29(10):1500-6. Epub 2009 Sep 3.
Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. Vutien P, Nguyen NH, Trinh HN, et al. J Gastroenterol. 2009 Nov 10. [Epub ahead of print]
Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. Grasso A, Malfatti F, De Leo P, et al. J Hepatol. 2009 Dec;51(6):984-90. Epub 2009 Jul 23.
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Grebely J, Petoumenos K, Matthews GV, et al. Drug Alcohol Depend. 2009 Nov 16. [Epub ahead of print]
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients* Giannini EG, Basso M, Savarino V, Picciotto A. Aliment Pharmacol Ther. 2009 Nov 19. [Epub ahead of print]
Mortality and drug exposure in a 5-year cohort of patients with chronic liver disease.
Hug BL, Lipsitz SR, Seger DL, et al. Swiss Med Wkly. 2009 Nov 19. [Epub ahead of print]
Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis. Olmez OF, Gurel S, Yilmaz Y. Eur J Gastroenterol Hepatol. 2009 Nov 24. [Epub ahead of print]
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. Zeremski M, Dimova R, Brown Q, et al. J Infect Dis. 2009 Dec 1;200(11):1774-80.
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor dependent manner. Mee CJ, Farquhar MJ, Harris HJ, et al. Gastroenterology. 2009 Nov 25. [Epub ahead of print]
Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. Gao QJ, Liu DW, Zhang SY, et al. World J Gastroenterol. 2009 Nov 28;15(44):5610-9.
Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment. Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G. AIDS Patient Care STDS. 2009 Nov 22. [Epub ahead of print]
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Bansi L, Turner J, Gilson R, et al. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):391-6.
Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Liver Int. 2009 Nov;29(10):1485-93. Epub 2009 Jul 7.
Psychiatric management of HIV/HCV- co-infected patients beginning treatment for hepatitis C virus infection: survey of provider practices. Weiss JJ, Morgello S. Gen Hosp Psychiatry. 2009 Nov-Dec;31(6):531-7. Epub 2009 Jun 9.
Survey of both hepatitis B virus (HBsAg) and hepatitis C virus (HCV-Ab) coinfection among HIV positive patients. Mohammadi M, Talei G, Sheikhian A, et al. Virol J. 2009 Nov 18;6(1):202. [Epub ahead of print]
Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS).
Frederick T, Burian P, Terrault N, et al. AIDS Patient Care STDS. 2009 Nov;23(11):915-23.
Long-term outcome of hepatitis B and hepatitis C virus co-infection and single HBV infection acquired in youth. Zampino R, Marrone A, Merola A, et al. J Med Virol. 2009 Dec;81(12):2012-20.
Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. Rozenberg L, Haagmans BL, Neumann AU, et al. AIDS. 2009 Nov 27;23(18):2439-50.
Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population.
Scott JD, Wald A, Kitahata M, et al. AIDS Patient Care STDS. 2009 Nov;23(11):925-9.
Lamiridosins, Hepatitis C Virus Entry Inhibitors from Lamium album.
Zhang H, Rothwangl K, Mesecar AD, Sabahi A, Rong L, Fong HH. J Nat Prod. 2009 Nov 11. [Epub ahead of print]
Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis.
Matsuoka S, Matsumura H, Nakamura H, et al. J Clin Biochem Nutr. 2009 Nov;45(3):292-303. Epub 2009 Oct 28.
Frequency of hepatitis C and d super infection in patients with hepatitis B related complex liver disorders. Baig S, Siddiqui AA, Ahmed WU, Qureshi H, Arif A. J Coll Physicians Surg Pak. 2009 Nov;19(11):699-703.
[Hepatitis C virus genotyping: Comparison of the Abbott RealTime HCV genotype II assay and NS5B sequencing.] [Article in French] Vaghefi P, Marchadier E, Dussaix E, Roque-Afonso AM. Pathol Biol (Paris). 2009 Nov 24. [Epub ahead of print]
Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.
Fierbinteanu-Braticevici C, Andronescu D, Usvat R, et al. World J Gastroenterol. 2009 Nov 28;15(44):5525-32.
Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Selzner N, Renner EL, Selzner M, et al. Transplantation. 2009 Nov 27;88(10):1214-21.
Needle sharing in regular sexual relationships: An examination of serodiscordance, drug using practices, and the gendered character of injecting. Bryant J, Brener L, Hull P, Treloar C. Drug Alcohol Depend. 2009 Nov 24. [Epub ahead of print]
Adverse outcomes in Alaska Natives who recovered from or have chronic hepatitis C infection. McMahon BJ, Bruden D, Bruce MG, et al.
The disposition of hepatitis C antibody-positive patients in an urban hospital. Putka B, Mullen K, Birdi S, Merheb M. J Viral Hepat. 2009 Nov;16(11):814-21.
Public health impact of antiviral therapy for hepatitis C in the United States.
Volk ML, Tocco R, Saini S, Lok AS. Hepatology. 2009 Dec;50(6):1750-5.